WEKO3
アイテム
{"_buckets": {"deposit": "c463fd99-8d43-4769-891d-1dc71ac48a15"}, "_deposit": {"id": "26904", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "26904"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00026904", "sets": ["501"]}, "author_link": ["88160", "88161", "88162", "88163", "88164", "88165", "88166", "88167", "88168", "88169", "88170"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "10", "bibliographicPageEnd": "1063", "bibliographicPageStart": "1059", "bibliographicVolumeNumber": "34", "bibliographic_titles": [{"bibliographic_title": "Pediatric Surgery International", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: Biliary atresia (BA) is characterized by progressive inflammation of the biliary system. This inflammation persists and causes liver fibrosis, although jaundice disappears after Kasai portoenterostomy (KP). We aimed to confirm whether the oral administration of eicosapentaenoic acid (EPA) suppresses liver fibrosis in postoperative patients with BA. Methods: We reviewed patients who underwent laparoscopic KP (lapKP) between January 2014 and September 2017. From December 2016, 30 mg/kg/day of EPA was orally administered to patients who opted to take medicine (EPA group). Patients who did not receive EPA were assigned to the non-EPA group. Mac-2 binding protein sugar chain modified isomer (M2BPGi) and hyaluronic acid (HA) levels were compared between the two groups in patients showing disappearance of jaundice at 6 months after the first lapKP. Results: Seventeen patients in the non-EPA group and 11 in the EPA group were enrolled. At 6 months after the first lapKP, 10 patients in the non-EPA group and six in the EPA group were without jaundice. M2BPGi and HA levels were significantly lower in the EPA group. Conclusions: Liver fibrosis was suppressed in patients without jaundice 6 months after lapKP, who were administered EPA. We believe that periductular inflammation was alleviated by EPA supplementation.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "ファイル公開:2019/10/01", "subitem_description_language": "ja", "subitem_description_type": "Other"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s00383-018-4313-6", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "“This is a post-peer-review, pre-copyedit version of an article published in [Pediatric Surgery International]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00383-018-4313-6”.", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_61": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0179-0358", "subitem_source_identifier_type": "PISSN"}]}, "item_10_source_id_62": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "1437-9813", "subitem_source_identifier_type": "EISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sumida, Wataru", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88160", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uchida, Hiroo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88161", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tainaka, Takahisa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88162", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shirota, Chiyoe", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88163", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hinoki, Akinari", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88164", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Takazumi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88165", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yokota, Kazuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88166", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oshima, Kazuo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88167", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shirotuki, Ryo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88168", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Chiba, Kosuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88169", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yujiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "88170", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-10-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "manuscript-final.pdf", "filesize": [{"value": "409.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 409000.0, "url": {"label": "manuscript-final", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/26904/files/manuscript-final.pdf"}, "version_id": "48a455a9-4aee-4533-98ea-11b97c2100f0"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Biliary atresia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Liver fibrosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Eicosapentaenoic acid", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Inflammation", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/00029107", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2018-12-13"}, "publish_date": "2018-12-13", "publish_status": "0", "recid": "26904", "relation": {}, "relation_version_is_last": true, "title": ["Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia"], "weko_shared_id": -1}
Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia
http://hdl.handle.net/2237/00029107
http://hdl.handle.net/2237/000291078d3d941d-5dab-4d61-9915-613a031d77c0
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-12-13 | |||||
タイトル | ||||||
タイトル | Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia | |||||
言語 | en | |||||
著者 |
Sumida, Wataru
× Sumida, Wataru× Uchida, Hiroo× Tainaka, Takahisa× Shirota, Chiyoe× Hinoki, Akinari× Kato, Takazumi× Yokota, Kazuki× Oshima, Kazuo× Shirotuki, Ryo× Chiba, Kosuke× Tanaka, Yujiro |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | “This is a post-peer-review, pre-copyedit version of an article published in [Pediatric Surgery International]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00383-018-4313-6”. | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Biliary atresia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Liver fibrosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Eicosapentaenoic acid | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Inflammation | |||||
抄録 | ||||||
内容記述 | Purpose: Biliary atresia (BA) is characterized by progressive inflammation of the biliary system. This inflammation persists and causes liver fibrosis, although jaundice disappears after Kasai portoenterostomy (KP). We aimed to confirm whether the oral administration of eicosapentaenoic acid (EPA) suppresses liver fibrosis in postoperative patients with BA. Methods: We reviewed patients who underwent laparoscopic KP (lapKP) between January 2014 and September 2017. From December 2016, 30 mg/kg/day of EPA was orally administered to patients who opted to take medicine (EPA group). Patients who did not receive EPA were assigned to the non-EPA group. Mac-2 binding protein sugar chain modified isomer (M2BPGi) and hyaluronic acid (HA) levels were compared between the two groups in patients showing disappearance of jaundice at 6 months after the first lapKP. Results: Seventeen patients in the non-EPA group and 11 in the EPA group were enrolled. At 6 months after the first lapKP, 10 patients in the non-EPA group and six in the EPA group were without jaundice. M2BPGi and HA levels were significantly lower in the EPA group. Conclusions: Liver fibrosis was suppressed in patients without jaundice 6 months after lapKP, who were administered EPA. We believe that periductular inflammation was alleviated by EPA supplementation. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
内容記述 | ||||||
内容記述 | ファイル公開:2019/10/01 | |||||
言語 | ja | |||||
内容記述タイプ | Other | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Springer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s00383-018-4313-6 | |||||
ISSN(print) | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 0179-0358 | |||||
ISSN(Online) | ||||||
収録物識別子タイプ | EISSN | |||||
収録物識別子 | 1437-9813 | |||||
書誌情報 |
en : Pediatric Surgery International 巻 34, 号 10, p. 1059-1063, 発行日 2018-10 |
|||||
著者版フラグ | ||||||
値 | author |